Literature DB >> 27175548

Assessment of Orthotopic Liver Transplant Graft Survival on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters.

Nina Bastati1, Andreas Wibmer, Dietmar Tamandl, Henrik Einspieler, Jacqueline C Hodge, Sarah Poetter-Lang, Susanne Rockenschaub, Gabriela A Berlakovich, Michael Trauner, Christian Herold, Ahmed Ba-Ssalamah.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the prognostic potential of a 3-parameter visual scoring (qualitative score [QS]) system for hepatobiliary phase gadoxetic acid-enhanced magnetic resonance imaging (MRI) in orthotopic liver transplant grafts.
MATERIALS AND METHODS: This retrospective study of 128 patients was approved by our institutional review board. Two readers independently assigned 3 QSs to T1-weighted MRI scans, 20 minutes after the administration of gadoxetic acid (hepatobiliary phase), based upon the following: (1) liver parenchymal enhancement (EnQS, 0-2); (2) biliary contrast excretion (ExQS, 0-2); and (3) signal intensity of the portal vein relative to the liver parenchyma, that is, the portal vein sign (PVsQS, 0-2). The functional liver imaging score (FLIS) was calculated as the sum score of these 3 parameters. The relative liver enhancement (RLE) was measured as well. Demographic, clinical, laboratory parameters, and imaging findings were included in univariate and multivariate statistical analyses. The primary end point was graft failure, that is, retransplantation or death from liver failure. The probability of graft survival was calculated by Kaplan-Meier estimates and Cox proportional hazards regression.
RESULTS: In the univariate analysis, EnQS, ExQS, PVsQS, and FLIS scores, as well as RLE, were significantly associated with the 1- to 3-year probability of graft survival (P < 0.001). For a FLIS of (0), the 3-year probability of graft survival was 6.5%, whereas it was 51.3% for a FLIS of (1-3) and 100% for a FLIS of (4-6) (P < 0.001). In the multivariate survival models, EnQS, ExQS, and PVsQS, each independently outperformed the majority of clinical and laboratory parameters, and the FLIS did even better regarding the prediction of 1- to 3-year graft survival.
CONCLUSIONS: In liver transplant recipients, gadoxetic acid-enhanced MRI-derived QSs (ie, EnQS, ExQS, and PVsQS), as well as the FLIS and RLE, can predict graft survival probability.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27175548     DOI: 10.1097/RLI.0000000000000286

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  11 in total

Review 1.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

2.  Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment.

Authors:  Francesco Verde; Valeria Romeo; Simone Maurea
Journal:  Quant Imaging Med Surg       Date:  2020-03

3.  Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.

Authors:  Chenxi Liu; Yan Sun; Yao Yang; Yuemin Feng; Xiaoyu Xie; Lingyu Qi; Keke Liu; Ximing Wang; Qiang Zhu; Xinya Zhao
Journal:  Eur Radiol       Date:  2021-02-03       Impact factor: 5.315

4.  Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS.

Authors:  Serdar Aslan; Uluhan Eryuruk; Merve Nur Tasdemir; Ismet Mirac Cakir
Journal:  Abdom Radiol (NY)       Date:  2022-06-07

5.  A functional liver imaging score for preoperative prediction of liver failure after hepatocellular carcinoma resection.

Authors:  Ningbin Luo; Xiangyang Huang; Yinan Ji; Guanqiao Jin; Yunying Qin; Bangde Xiang; Danke Su; Weizhong Tang
Journal:  Eur Radiol       Date:  2022-03-16       Impact factor: 7.034

6.  Detecting liver fibrosis with Gd-EOB-DTPA-enhanced MRI: A confirmatory study.

Authors:  Niklas Verloh; Kirsten Utpatel; Michael Haimerl; Florian Zeman; Lukas Beyer; Claudia Fellner; Frank Brennfleck; Marc H Dahlke; Christian Stroszczynski; Matthias Evert; Philipp Wiggermann
Journal:  Sci Rep       Date:  2018-04-18       Impact factor: 4.379

7.  Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI.

Authors:  Lukas Haider; Mattias Mandorfer; Zeynep Güngören; Thomas Reiberger; Nina Bastati; Jacqueline C Hodge; David Chromy; Michael Trauner; Christian Herold; Markus Peck-Radosavljevic; Ahmed Ba-Ssalamah
Journal:  Contrast Media Mol Imaging       Date:  2018-07-12       Impact factor: 3.161

Review 8.  Quantification of liver function using gadoxetic acid-enhanced MRI.

Authors:  Sarah Poetter-Lang; Nina Bastati; Alina Messner; Antonia Kristic; Alexander Herold; Jacqueline C Hodge; Ahmed Ba-Ssalamah
Journal:  Abdom Radiol (NY)       Date:  2020-10-09

9.  Total Bilirubin Level as a Predictor of Suboptimal Image Quality of the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI in Patients with Extrahepatic Bile Duct Cancer.

Authors:  Jeong Ah Hwang; Ji Hye Min; Seong Hyun Kim; Seo-Youn Choi; Ji Eun Lee; Ji Yoon Moon
Journal:  Korean J Radiol       Date:  2022-01-04       Impact factor: 3.500

Review 10.  Assessment of Liver Function With MRI: Where Do We Stand?

Authors:  Carolina Río Bártulos; Karin Senk; Mona Schumacher; Jan Plath; Nico Kaiser; Ragnar Bade; Jan Woetzel; Philipp Wiggermann
Journal:  Front Med (Lausanne)       Date:  2022-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.